A Phase II Trial of ABI-007 (Paclitaxel Albumin-bound Particles) for the Prevention of Restenosis Following Revascularization of the Superficial Femoral Artery (SFA).
Phase of Trial: Phase II
Latest Information Update: 12 Mar 2012
At a glance
- Drugs Paclitaxel (Primary)
- Indications Restenosis
- Focus Therapeutic Use
- 12 Mar 2012 Company added as trial sponsor and additional lead trial centre identified as reported by ClinicalTrials.gov.
- 06 Oct 2011 Actual end date (September 2009) added as reported by ClinicalTrials.gov.
- 21 Oct 2009 Actual patient number (228) added as reported by ClinicalTrials.gov.